Gyre Therapeutics (NASDAQ:GYRE) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Gyre Therapeutics (NASDAQ:GYRE) from a sell rating to a hold rating in a research note released on Saturday morning,Wall Street Zen reports.

A number of other research analysts also recently weighed in on GYRE. Zacks Research raised Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Gyre Therapeutics in a research note on Wednesday, November 4th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce”.

Gyre Therapeutics Trading Down 2.3%

GYRE opened at $4.65 on Friday. Gyre Therapeutics has a 1-year low of $3.97 and a 1-year high of $9.14. The company has a market cap of $518.52 million, a P/E ratio of -23.25 and a beta of 2.14. The company has a fifty day moving average price of $6.47 and a two-hundred day moving average price of $6.89.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.19. The company had revenue of $32.93 million for the quarter, compared to analysts’ expectations of $28.40 million. Gyre Therapeutics had a negative net margin of 15.47% and a negative return on equity of 6.57%. On average, research analysts forecast that Gyre Therapeutics will post -0.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Gyre Therapeutics

A number of hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Gyre Therapeutics in the second quarter valued at about $6,550,000. SBI Securities Co. Ltd. lifted its position in shares of Gyre Therapeutics by 1.8% during the third quarter. SBI Securities Co. Ltd. now owns 169,717 shares of the company’s stock valued at $1,244,000 after purchasing an additional 2,967 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in Gyre Therapeutics during the second quarter worth about $414,000. Dimensional Fund Advisors LP boosted its holdings in Gyre Therapeutics by 131.8% during the first quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock worth $176,000 after purchasing an additional 14,365 shares during the last quarter. Finally, Deutsche Bank AG purchased a new position in Gyre Therapeutics during the second quarter worth about $118,000. 23.99% of the stock is owned by hedge funds and other institutional investors.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a biopharmaceutical company focused on developing therapies for fibrotic diseases, including pulmonary and liver fibrosis. The company’s lead development program is F351, also known as hydronidone, an investigational small-molecule therapy designed to inhibit the progression of fibrosis.

F351 is being evaluated in clinical programs for idiopathic pulmonary fibrosis and liver fibrosis associated with chronic liver disease, including nonalcoholic steatohepatitis-related fibrosis.